Algorae Pharmaceuticals (ASX:1AI) Tariff Resilience Score: 6/10 (As of Jun. 28, 2026)


What is Algorae Pharmaceuticals Tariff Resilience Score?

Algorae Pharmaceuticals ASX:1AI Tariff Resilience Score is 6 as of Jun. 28, 2026. The stock has 2 warning signs investors should review. Among 1,376 Biotechnology companies, Algorae Pharmaceuticals ranks better than 75.94% on this metric.

Algorae Pharmaceuticals has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Algorae Pharmaceuticals has Algorae Pharmaceuticals faces tariff risks due to its global supply chain for raw materials. However, the pharmaceutical industry often benefits from tariff exemptions, reducing vulnerability. The company has some pricing power to offset potential cost increases.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Algorae Pharmaceuticals might have Average Resilient.

Algorae Pharmaceuticals  (ASX:1AI) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Algorae Pharmaceuticals Tariff Resilience Score Related Terms

ASX:1AI vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Algorae Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Algorae Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algorae Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Algorae Pharmaceuticals's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 6 mean?
Algorae Pharmaceuticals (ASX:1AI) has a Tariff Resilience Score of 6 as of Jun. 28, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Algorae Pharmaceuticals ranks #331 out of 1376 companies in the Biotechnology industry, placing it in the top 24.1%.
Is Algorae Pharmaceuticals' Tariff Resilience Score too high?
Algorae Pharmaceuticals' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Algorae Pharmaceuticals' value of 6 is 50% above this industry median. Based on the distribution chart, Algorae Pharmaceuticals ranks #331 out of 1376 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Algorae Pharmaceuticals' Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Algorae Pharmaceuticals ranks #331 out of 1376 companies for Tariff Resilience Score. This places Algorae Pharmaceuticals in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Algorae Pharmaceuticals' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,376 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Algorae Pharmaceuticals's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Algorae Pharmaceuticals's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Algorae Pharmaceuticals stock overvalued right now?
Algorae Pharmaceuticals (ASX:1AI) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Algorae Pharmaceuticals (ASX:1AI), the current Tariff Resilience Score is 6 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Algorae Pharmaceuticals Business Description

Other Exchanges LVCLF:USALHI0:Germany
Address 525 Collins Street, Level 23, Rialto South Tower, Melbourne, VIC, AUS, 3000
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer's disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.